FDA advisory panel set to evaluate Grail's Galleri multi-cancer early detection test

According to reporting in STAT News, a US Food and Drug Administration advisory panel is due to convene to evaluate Grail's Galleri test, a blood-based multi-cancer early detection (MCED) test that uses cell-free DNA methylation patterns to signal the presence of more than 50 cancer types and identify the tissue of origin.

Galleri has been commercially available in the United States on a cash-pay basis since 2021 and has been the subject of large prospective studies, including the NHS-Galleri trial in England, which enrolled approximately 140,000 participants. FDA advisory committee meetings are a key step in the US regulatory review process for novel diagnostics; the panel's deliberations and vote will inform, but do not bind, a final FDA decision on approval.

The test represents a significant area of scientific and commercial interest in oncology, genomics, and public health, given questions about the clinical utility, optimal screening populations, and health-economic implications of population-level cancer signal detection. The advisory committee review is expected to examine the evidence from pivotal studies on sensitivity, specificity, and positive predictive value across cancer types.

This item is based on a STAT News news brief; full committee proceedings and primary evidence summaries will be published by the FDA ahead of the meeting.